1. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Issue 8 (August 2022) Authors: Pautier, Patricia; Italiano, Antoine; Piperno-Neumann, Sophie; Chevreau, Christine; Penel, Nicolas; Firmin, Nelly; Boudou-Rouquette, Pascaline; Bertucci, François; Balleyguier, Corinne; Lebrun-Ly, Valérie; Ray-Coquard, Isabelle; Kalbacher, Elsa; Bardet, Aurélie; Bompas, Emmanuelle; Collard, Olivi... Journal: Lancet oncology Issue: Volume 23:Issue 8(2022) Page Start: 1044 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗